Question.2480 - 1.) What are some reasons you can think of that more males than females worldwide use drugs?2.) Older people are at a greater risk of adverse drug interactions. What are some reasons for this? As stated in the text, "A 'new' drug may be a novel molecular synthesis, a recombination of known ingredients, or a new use of an existing compound. In all these cases, the FDA has guidelines that must be met to make a 'new drug application,' which must be approved before a drug can be marketed." 3.) About how long does each step in the development of a new drug take to complete? What is one advantage and one disadvantage of this? 4.) Stimulant drugs have been found to help children diagnosed with ADHD to focus their attention on schoolwork in school. What are some advantages to this that its proponents cite? What do you think about these? What are some disadvantages to treating ADHD with stimulants, as cited by its opponents? What do you think about these?
Answer Below:
Drugs xx substance xxxxx means xxxxx are xxxxxxx chemicals xxxx are xxxx with xxx intent xx create xxxxxxxxxxx effects xx the xxxxx For xxxx reason xxx are xxxx addicted xx drugs xxxx females xxxx studies xxxx also xxxxxx that xxxx addiction xx more xxxxxx in xxx when xxxxxxxx to xxxxxxx Some xxxxxxx that xxx be xxxxxxxxx are x Males xxxxx using xxxxx at xx early xxx which xxxxx them xxxx addicted xx drugs xxxxx company xx stress xxx be x path xxxx can xxxx to xxxxxx drugs xxx when xxxxx on x daily xxxxx or xxxxxxxxxx can xxxxxx a xxxxx because xx which xxxxx are xxxx addicted xx drugs xxxx is xxxxx simple xx understand xxxx males xxxxx drugs xxxx often xxxxx is xxxxxxxxx use xx the xxxxxxxxx which xxxxx them xxxx addicted xxxxxxx and xxxxxxx are xxxx consumed xx males xxx their xxxxxxxx and xx avoid xxxxxx and xxxxx also xxxx them xxxx addicted xx taking xxxxx Formica xx al xxx more xxxxxx can xx that xx a xxxxx period xxxxx are xxxx to xxxxxxx different xxxxx of xxxxxx which xxxxx they xxxxxx in xxxxx drinking xxxxx gives xxxx more xxxxxxxx in x short xxxxxx of xxxx and xxxxx it xxxxxxx their xxxxx which xxxxx them xxxx addicted xx drugs xxxx females xxxxx people xxxxxxxxx have xxxx weight xxxxxxx their xxxx size xxxxxxxxx which xxxx that xxxxx is xxxx presence xx fat xx the xxxx and xxxx amount xx water xxx these xxxxx when xxxxxxxx get xxxxxxxxxxx in xxx body xxxxxxx of xxx decreased xxxxx and xxxxxx function xxxxx is xxxxxxxxx to xxxxx health xxxxx individuals xxx sensitive xx many xxxxx so x smaller xxxx of xxx same xxxx must xx given xx them xx check xx it xxxxxx any xxxx effects xxxxx people xxx at xxxxxxx risk xxxx using xxxxx as xx can xxxxxx and xxxxx side xxxxxxx that xxx commonly xxxx The xxxxxx side xxxxxxx can xx dizziness xxxxxx gain xx weight xxxx there xxx be xxxxxxx in xxx memory xxxxx means xxxxxxxxxx memory xxxx problems xxxxx problems xxx affect xxxxx people xxx disturb xxxxxx functioning xx day-to-day xxxx Sen xx al xxxxxxx drug xxxxxxxxxxx in xxxxx people xxx cause xxxx other xxxxxxxx such xx diarrhoea xxxx rashes xxxxxxxx headache xxx mouth xxx by xxx these xxxxxxxx will xxxxxxxxxxx the xxxxxx of xxxxx individuals xxxxx side xxxxxxx can xxxxxx the xxxxx heart xxxxxx and xxxxx parts xx the xxxx and xxx eventually xxxx to xxxxx The xxxxx must xx given xx prescribed xx the xxxxxxxxxx professionals xxxxxxxxx more xxxxxx of xxxxx drugs xxx cause xx adverse xxxxxx on xxx mind xxx body xx older xxxxxx Discussion xxxxx are xxxx to xxxx phases xxxxx which xxx development xx a xxx drug xxxxx place x new xxxx takes xxxxxxx years xx be xxxxxx and xxxx clinical xxxxxx are xxxx before xx ensure xxxx it xxx the xxxxx side xxxxxxx and xxx actually xxxxx the xxxxxxxxxx disease xxx entire xxxxxxxxxxx process xx a xxx drug xxxxx about xxx to xxxxxx years xx sometimes xxxx than xxxx While xxxxxxxxxx a xxx drug xx has xx pass xxxxxxx all xxx phases xxx tests xxx then xx is xxxxxxxxxx marketed xxxxx being xxxxxxxx by xxx food xxx distribution xxxxxxxxxxxxxx that xx FDA xxx food xxx distribution xxxxxxxxxxxxxx takes xxxxxx on xxx new xxxx application xxxxxx six xxxxxx The xxxxxxxxxxx of x new xxxx benefits xxx patients xxx it xxxx benefits xxx whole xxxxxxx Patton xxx amp xxxxxxxx The xxx drug xxx s xxxxxxx is xxxx it xxxxxx the xxxxxxxxx of xxx disease xxx it xxxx has xxxxxxxx benefits xxxxx are xxxx challenges xx the xxxxxxx of xxxxxxxxxxx of xxx new xxxxx as xxxxx are x lot xx failed xxxxxxxx trials xxxxxxxxx huge xxxxxxxxxx is xxxxxxxx to xxxxxxx a xxx drug xxxxx is xxxx a xxxx of xxxxxxx animal xxxxxx which xx a xxxxxxx to xxx development xx new xxxxx Stimulant xxxxx are xxxxxxxxx in xxxxxxx which xxx problem xx ADHD xxxxx is xxxxxxxxx deficit xxxxxxxxxxxxx disorder xxxxx problems xxx mostly xxxxx by xxxxxxxx The xxxxxxxx of xxxx disorder xxx short xxxxxxxxx span xxxxxxxxx behaviour xxx hyperactivity xxx stimulant xxxxx help xxxxxxx the xxxxxxxxxx and xxxxxx interrupting xxxxxxxxx fidgeting xxx advantage xx stimulant xxxxx is xxxx it xxxxxxxx the xxxxxxxx amp x conditions xxx helps xxxx focus xx schoolwork xx school xxx drugs xxxx to xxxxxxxx the xxxxxxx of xxxxx attention xxxx it xxxx increases xxxxxxxxx power xxxx Morsy xxx amp xxxxx Stimulant xxxxx help xxx children xx overcome xxxxx anxiety xx mood xxxxxx and xxxxx down xxx other xxxxxxxx of xxxx Every xxxxxxxxxx has xxxx side xxxxxxx or xxxxxxxxxxxxx and xx the xxxxx which xxx able xx treat xxxx disorder xxxx have xxxx disadvantages xxxx as xxxxx can xx heart xxxxxxxx which xxxxx it xxx lead xx high xxxxx pressure xx increased xxxxx rates xxxxx drugs xxx even xxxx to xxxxxxxxxxx problems xx suicidal xxxxx The xxxxxxxxxxx problem xxxxxx to x high xxxx for xxxxxxxxx or xxxxx systems xxx children xxx see xx hear xxxxxx that xxx not xxxx If xxxx situation xxxxx it xx advised xx take xxx children xx the xxxxxx There xx also x possibility xx suicidal xxxxx as xxxxxxxx or xxxxxxxxx can xxxxx to xxxxxxx suicide xxxxx problems xxx rare xxx there xxx be x possibility xx these xxxxxx risks xxxxxxxxxx References xxxxxxx M x amp xxx Petroni x R xxx impact xx early-phase xxxxx design xx the xxxx development xxxxxxx Clinical xxxxxx Research x Retrieved xxxx https xxxxxxxxxxxxx aacrjournals xxx content xxxxxxxxxx full xxx Formica x Sultana x Cutroneo x M xxxxxxxx S xxxxxxxx R xxxxxxxxxx S xxx amp xxxxxx ograve x The xxxxxxxx burden xx preventable xxxxxxx drug xxxxxxxxx a xxxxxxxxxx review xx observational xxxxxxx Expert xxxxxxx on xxxx safety x Retrieved xxxx https xxx cleandrugs xx articulos xxxxxxx - xxxxx ESTADIA xxxxxxxxxxxx INCIDENCIA xxxxx NIBLES xxx Nair x Morsy x A xxx amp xxxxx S xxxx translation xxxxxxx laboratory xxxxxxx and xxxxx in xxxxxxxxxxx and xxxxxxxx phases xx drug xxxxxxxxxxx Drug xxxxxxxxxxx research x Retrieved xxxx https xxx researchgate xxx profile xxxxxxx Nair xxxxxxxxxxx Dose xxxxxxxxxxx between xxxxxxxxxx animals xxx hu xxx in xxxxxxxxxxx and xxxxxxxx phases xx drug xxxxxxxxxxx links xx f x bf x Dose-translation-between-laboratory-animals-and-human-in-preclinical- xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx pdf xxxxxx K xxx amp xxxxxxxx D x Adverse xxxx reactions xxxxxxxxxxx - xxxxxxxxx from xxxxx associationofanaesthetists- xxxxxxxxxxxx onlinelibrary xxxxx com xxx pdf xxxx Sen x Jette x Husain x amp xxx Sander x W xxxxxxxx in xxxxx people xxx Lancet x Retrieved xxxx https xxxxxxxxx ucl xx uk xx eprint xxxxxxxx and xxx elderly xxxxxx revised xxxxx pdfMore Articles From Medicine
.ico)
.ico)
.ico)
.ico)
